(0.25%) 5 144.25 points
(0.26%) 38 541 points
(0.36%) 17 911 points
(-0.81%) $83.17
(1.92%) $1.960
(-0.17%) $2 343.20
(1.26%) $27.60
(0.70%) $928.60
(-0.24%) $0.932
(-0.29%) $10.99
(-0.32%) $0.798
(0.75%) $92.56
Quarter results tomorrow
(bmo 2024-04-30)
Expected move: +/- 5.21%
-0.29% INR 50.85
Live Chart Being Loaded With Signals
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India...
Stats | |
---|---|
Tagesvolumen | 1.86M |
Durchschnittsvolumen | 6.15M |
Marktkapitalisierung | 25.99B |
EPS | INR0 ( 2024-04-12 ) |
Nächstes Ertragsdatum | ( INR0 ) 2024-04-30 |
Last Dividend | INR0.600 ( 2002-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 33.90 |
ATR14 | INR0.0690 (0.14%) |
Volumen Korrelation
Morepen Laboratories Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Morepen Laboratories Korrelation - Währung/Rohstoff
Morepen Laboratories Finanzdaten
Annual | 2022 |
Umsatz: | INR14.18B |
Bruttogewinn: | INR4.62B (32.58 %) |
EPS: | INR0.770 |
FY | 2022 |
Umsatz: | INR14.18B |
Bruttogewinn: | INR4.62B (32.58 %) |
EPS: | INR0.770 |
FY | 2022 |
Umsatz: | INR15.42B |
Bruttogewinn: | INR4.81B (31.18 %) |
EPS: | INR2.26 |
FY | 2021 |
Umsatz: | INR11.75B |
Bruttogewinn: | INR3.89B (33.06 %) |
EPS: | INR2.16 |
Financial Reports:
No articles found.
Morepen Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR0.600 | 2000-04-28 |
Last Dividend | INR0.600 | 2002-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 2002-10-08 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | INR2.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.52 | -- |
Div. Sustainability Score | 2.95 | |
Div.Growth Potential Score | 3.51 | |
Div. Directional Score | 3.23 | -- |
Year | Amount | Yield |
---|---|---|
2000 | INR0 | 0.00% |
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SMLT.NS | Dividend Knight | 2023-08-09 | Semi-Annually | 3 | 0.64% | |
MIDHANI.NS | Dividend Junior | 2023-09-22 | Semi-Annually | 7 | 1.04% | |
HAVELLS.NS | Dividend Junior | 2023-06-02 | Annually | 23 | 0.43% | |
BECTORFOOD.NS | Dividend Junior | 2023-09-22 | Semi-Annually | 4 | 0.39% | |
PUNJABCHEM.NS | Dividend Junior | 2023-07-27 | Sporadic | 18 | 0.16% | |
KENNAMET.NS | Dividend Knight | 2023-05-25 | Annually | 4 | 0.76% | |
ELECTCAST.NS | Dividend Junior | 2023-09-04 | Annually | 23 | 1.51% | |
AHLUCONT.NS | Dividend Junior | 2023-09-22 | Sporadic | 15 | 0.04% | |
SUNPHARMA.NS | Dividend Junior | 2023-07-28 | Semi-Annually | 29 | 0.77% | |
NAVA.NS | Dividend Knight | 2023-07-24 | Annually | 23 | 2.35% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0467 | 1.500 | 9.07 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0988 | 1.500 | -0.0137 | -0.0206 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 31.04 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.206 | 2.00 | 9.60 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.206 | 2.00 | 9.40 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.359 | 1.000 | 7.36 | 7.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0661 | 1.000 | -0.678 | -0.678 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.95 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.25 | 1.000 | 6.64 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0988 | 2.50 | -0.00883 | -0.0206 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.206 | 2.00 | 9.60 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.206 | 2.00 | 9.60 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 7.40 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0378 | 1.000 | -1.555 | 0 | [0.1 - 0.5] |
Total Score | 3.51 |
Morepen Laboratories
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.